<DOC>
	<DOCNO>NCT00199797</DOCNO>
	<brief_summary>Although treatment metastatic colo-rectal cancer improve significantly recent year , still remain significant health problem represent lead cancer incidence United States America . In search new therapy monoclonal antibody develop specifically target human colon cancer cell . huA33 antibody react A33 antigen produce colorectal cancer . Prior study show application huA33 antibody may delay growth tumor cell produce respective antigen . Oxaliplatin 5-FU cytotoxic agent consider standard treatment metastatic colorectal cancer . Leucovorin vitamin enhances effect 5FU . Eligible patient advanced colorectal cancer receive huA33 , 10 mg/m2 intravenous ( IV ) infusion weekly twelve week . On Study Day 15 ( week 3 ) , 5-FU , leucovorin ( folinic acid ) , oxaliplatin administer every 2 week 10 week . Patients evaluate weekly toxicity . Blood sample obtain every week hematology serum biochemistry analysis determination human anti-human antibody ( HAHA ) . In patient measurable disease , tumor assess appropriate scan baseline end thirteen week cycle . The primary objective study assess safety huA33 + 5FU + leucovorin + oxaliplatin . The secondary objective measure immunogenicity huA33 give combination 5FU plus leucovorin oxaliplatin document tumor response .</brief_summary>
	<brief_title>Phase I Trial huA33 Plus Chemotherapy Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description>Purpose Research Study : huA33 antibody react A33 antigen produce colorectal cancer . Prior study show application huA33 antibody may delay growth tumor cell produce respective antigen . Oxaliplatin 5-FU cytotoxic agent consider standard treatment metastatic colorectal cancer . Leucovorin vitamin enhances effect 5FU . The primary purpose study determine whether combination huA33 plus Oxaliplatin , 5-FU Leucovorin safe side effect occur . Description Research Procedures : The first step determine whether patient eligible participation study . Apart general blood test x-ray study need , involve test regard special requirement : - Three test stool determine positive blood . - Women childbearing age must negative pregnancy test . - If patient ever treatment similar substance like huA33 , blood sample need test antibody may develop huA33 . After eligibility establish , huA33 administer intravenously period 30 minute week dose 10 mg/m2 . Every second week , Oxaliplatin , 5-FU Leucovorin administer additionally . Oxaliplatin Leucovorin give infusion 2 hour . Afterwards patient receive bolus infusion 5-FU intravenously follow infusion 5-FU 22 hour . The dos Oxaliplatin 85mg/m2 , Leucovorin 200mg/m2 , 400mg/m2 5-FU bolus infusion 600mg/m2 continuous infusion . A complete treatment cycle consist 12 weekly treatment day . Patients interview doctor physical examination first day treatment therapy . Standard blood test well special blood test measure possible reaction immune system huA33 antibody do weekly treatment start . The amount blood draw 20-30 ml one cycle study . X-rays and/or CT scan measure extend disease do start week 12 , consider first day next cycle . Patients may continue treatment evidence tumor progression .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Patients eligible enrollment fulfill follow criterion : 1 . Metastatic colorectal cancer 2 . Histologically cytologically proven colorectal cancer 3 . Expected survival least 4 month . 4 . Not 2 different pretreatment regimens 5 . ECOG performance status 02 . 6 . Within 2 week prior first dose huA33 , follow vital laboratory parameter : Lab Parameter Range Neutrophil count &gt; 1.5 x 109/L Platelet count &gt; 150 x 109/L Serum bilirubin &lt; 2 mg/dL Creatinine clearance &gt; 50 ml/ min 7 . Age â‰¥ 18 year 8 . Able willing give valid write informed consent Patients exclude study follow reason : 1 . Untreated active metastatic disease central nervous system define new enlarge lesion CT MRI . 2 . Surgery radiotherapy brain metastasis within 3 month prior first dose huA33 . 3 . Metastatic disease involve &gt; 50 % liver volume . 4 . Other serious illness , eg , serious infection require antibiotic , bleed disorder . 5 . Chemotherapy , radiation therapy , immunotherapy within 4 week prior first dose ( 6 week nitrosoureas ) . 6 . Previous treatment Oxaliplatin . 7 . Previous treatment huA33 monoclonal antibody antibody fragment . 8 . Concomitant treatment systemic corticosteroid . Topical inhalational corticosteroid permit . 9 . Known HIV , Hepatitis B C positivity . 10 . Mental impairment may compromise ability give informed consent comply requirement study . 11 . Lack availability patient clinical laboratory followup assessment . 12 . Participation clinical trial involve another investigational agent within 4 week prior first dose . 13 . Pregnancy breastfeed . 14 . Women childbearing potential : Refusal inability use effective mean contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Colorectal Cancer</keyword>
	<keyword>huA33</keyword>
	<keyword>antibody</keyword>
	<keyword>chemotherapy</keyword>
</DOC>